|
|||||
|
|
Staging of α‐synuclein in the olfactory bulb in a model of Parkinson's disease: Cell types involved |
|
| Authors: | Isabel Ubeda‐Bañon MSc Daniel Saiz‐Sanchez BSc Carlos de la Rosa‐Prieto MSc Alicia Mohedano‐Moriano PhD Noelia Fradejas MSc Soledad Calvo MD PhD Lucia Argandoña‐Palacios MD Susana Garcia‐Muñozguren MD Alino Martinez‐Marcos PhD |
| Affiliation: | 1. Laboratorio de Neuroanatomía Humana, Departamento de Ciencias Médicas, Facultad de Medicina, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla‐La Mancha, Spain;2. Laboratorio de Glia e Isquemia, Departamento de Ciencias Médicas, Facultad de Medicina, Universidad de Castilla‐La Mancha, Spain;3. Complejo Hospitalario Universitario de Albacete, Servicio de Neurología, Spain |
| Abstract: | Impaired olfaction is an early symptom of Parkinson's disease. The underlying neuropathology likely includes α‐synucleinopathy in the olfactory bulb at an earlier stage (Braak's stage1) than pathology in the substantia nigra, which is not observed until stage 3. In this report, we investigated the distribution and cell types affected by α‐synuclein in the olfactory bulb of transgenic mice (2–8 months of age) expressing the human A53T variant of α‐synuclein. α‐Synuclein immunostaining progressively affects interneurons and mitral cells. Double labeling studies demonstrate that dopaminergic cells are hardly involved, whereas glutamatergic‐ and calcium binding protein‐positive cells are severely affected. This temporal evolution and the cell types expressing α‐synuclein are reminiscent of idiopathic Parkinson's disease and support the usefulness of this model to address specific topics in the premotor phase of the disease. © 2010 Movement Disorder Society |
| Keywords: | α ‐Synuclein calcium binding protein olfactory bulb olfactory deficit Parkinson's disease transgenic mice tyrosine hydroxylase |